ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions
View by Date

Monday, November 11, 2019

9:00AM-11:00AM
Abstract Number: 1642
Automated Nailfold Capillary Counting System (AUTOCAPI) in Systemic Sclerosis Patients with Different Capillaroscopic Patterns
Systemic Sclerosis & Related Disorders – Clinical Poster II
9:00AM-11:00AM
Abstract Number: 1708
Azathioprine and Glucocorticoid Combination Might Be a Good Treatment Option to Achieve Remission in Patients with IgG4-related Disease
Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides
9:00AM-11:00AM
Abstract Number: 1455
B and T Cell Immunologic Features Associated with Higher Disease Activity Score and Focus Score in Primary Sjögren Syndrome
Sjögrenʼs Syndrome – Basic & Clinical Science Poster II
9:00AM-11:00AM
Abstract Number: 1416
B Cell Profile for Early Identification of Optimal Responders to TNF-inhibitors in Rheumatoid Arthritis
RA – Treatments Poster II: Established Treatments
9:00AM-11:00AM
Abstract Number: 971
B Cell ROCK1 Promotes Germinal Center Responses and Is Required for Optimal Humoral Immunity
B Cell Biology & Targets In Autoimmune & Inflammatory Disease Poster
9:00AM-11:00AM
Abstract Number: 1407
Baricitinib Provides Better Pain Relief Across All Disease Activity Levels Compared with Placebo and Adalimumab in Rheumatoid Arthritis
RA – Treatments Poster II: Established Treatments
9:00AM-11:00AM
Abstract Number: 1142
Barriers and Facilitators of Medication Adherence Among Minority SLE Patients: A Qualitative Study
Healthcare Disparities In Rheumatology Poster
9:00AM-11:00AM
Abstract Number: 1453
Baseline EULAR Sjögren’s Syndrome Patient-Reported Index Has a Significant Impact on the Longitudinal Course of Sjögren’s Syndrome
Sjögrenʼs Syndrome – Basic & Clinical Science Poster II
9:00AM-11:00AM
Abstract Number: 1626
Baseline Serum Osteopontin (OPN) Level Is Associated with Early Coronary Artery-calcification and Its Progression in Patients with Systemic Lupus Erythematosus
SLE – Clinical Poster II: Comorbidities
9:00AM-11:00AM
Abstract Number: 1650
Baseline Skin Score, Older Age and CD34-selection Influence the Outcome of Autologous Stem Cell Transplantation for Systemic Sclerosis – Results of a Prospective Non-interventional Study from the European Society for Blood & Marrow Transplantation (EBMT)
Systemic Sclerosis & Related Disorders – Clinical Poster II
9:00AM-11:00AM
Abstract Number: 1189
Baylor Rheumatology Initiative: Developing and Guiding Engagement (BRIDGE) Transition Pathway Creation and Implementation
Measures Of Healthcare Quality Poster II: Improving Care
9:00AM-11:00AM
Abstract Number: 1059
BDCA2 Targeting of Human Plasmacytoid Dendritic Cells via CBS004 Reverts Dependent IFN Activation and Tissue Fibrosis in vitro and in vivo
Systemic Sclerosis & Related Disorders – Basic Science Poster
9:00AM-11:00AM
Abstract Number: 1002
Beneficial Effect of Angiotensin Receptor Blocker in a Spondyloarthritis Animal Model
Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster
9:00AM-11:00AM
Abstract Number: 1540
Biologic Use and Reasons for Switching Biologic Therapy in Patients with Non-radiographic Axial Spondyloarthritis in the United States:Findings from a US Survey
Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis
9:00AM-11:00AM
Abstract Number: 1693
Biological Therapy in Neurobehçet: Multicenter Study of 31 Patients
Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Behçet’s Disease & Other Vasculitides
  • «Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 65
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology